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(20%). Quality of life, documented with a generic (EQ-
5D) and a disease-specific questionnaire (IBSQOL), showed
that patients are severely affected by IBS. The EQ-5D tar-
iff was decreased to 0.63. The IBSQOL showed that peo-
ple have strong discomfort in daily activities, and mood
and food intake are affected. CONCLUSION: It is obvi-
ous that a reduction in severity of disease will reduce so-
cietal as well as social sickness fund costs. In further re-
search, we will use data to model estimated cost savings
obtained through the introduction of new therapeutic op-
tions with increased effectiveness.
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OBJECTIVE: Patient-reported symptom severity mea-
sures are important for evaluating the effectiveness of
treatments for gastrointestinal diseases because they are
the only measures in clinical evaluation that directly re-
flect the patient experience. Gastroparesis refers to ab-
normal gastric emptying, encompassing a variety of up-
per gastrointestinal symptoms that are difficult to quantify.
The purpose of this study is to describe the development
and initial testing of a new self-report measure, the Pa-
tient Assessment of Upper GastroIntestinal Disorders-
Symptom Severity Index (PAGI-SYM) in subjects with
gastroparesis. METHODS & RESULTS: Instrument
content was based on a review of the published literature
and patient and clinician interviews. The 37-item PAGI-
SYM is comprised of six subscales: heartburn, reflux/re-
gurgitation, nausea/vomiting, abdominal pain, bloating/
early satiety, and other symptoms. Psychometric evalua-
tion of the PAGI-SYM in 120 subjects with gastroparesis
identified through six clinical sites in the US is currently
being completed. Subjects complete the PAGI-SYM, the
SF-36, and a measure of patient-rated change in gastro-
paresis-related symptoms, the Overall Treatment Effect
Scale (OTE), by way of telephone interview. Two-week
reproducibility will be evaluated in 30 subjects. The
PAGI-SYM will be analyzed for internal consistency reli-
ability, reproducibility, and validity. 104 subjects have
been enrolled in the study to date. Data collection is pro-
ceeding with data analysis to be completed by October 1.
CONCLUSION: The results of this study will provide
valuable information on the psychometric properties of
the PAGI-SYM. 
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OBJECTIVES: In recent clinical trials, esomeprazole, a
new proton pump inhibitor, has been shown to be effec-
tive for long-term on demand treatment (medication taken
as needed) to control recurrent symptoms in patients
with Gastro-Oesophageal Reflux Disease (GORD) with-
out oesophagitis. The objective of this analysis was to
evaluate the cost-effectiveness of on demand treatment
with esomeprazole, 20 mg, compared with intermittent
treatment courses with omeprazole, 20 mg, od, or contin-
uous omeprazole treatment following relapse in patients
with GORD without oesophagitis. METHODS: A simple
Markov model was designed to compare the cost-effec-
tiveness of esomeprazole on demand treatment for six
months with a strategy comprising intermittent treatment
courses of omeprazole. In a further comparison, the strict
intermittent omeprazole strategy was replaced by a strat-
egy where continuous treatment was prescribed follow-
ing a first relapse, which better reflects conventional care.
Patient management was based on results from a UK
physician survey of patient management in clinical prac-
tice. The UK survey results were adjusted for Finland and
Sweden based on expert opinions. Direct medical costs in
Finland, Sweden and the UK were used. Time with
GORD, defined as weeks with symptoms during relapses,
was used as the measure of effectiveness. RESULTS: Time
with GORD was 0.4 weeks per patient in the esomepra-
zole on demand strategy, 2.2 weeks in the intermittent
omeprazole strategy and 1.8 weeks in the conventional
omeprazole strategy. The esomeprazole strategy incurred
lower costs than either omeprazole strategy. This analysis
represents a conservative estimate of the cost-effective-
ness of on demand treatment with esomeprazole, since
data from clinical trials using placebo plus antacids as
rescue medication were used as a substitute for relapse in
patients with GORD without oesophagitis.
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OBJECTIVES: Patients with Gastro-Oesophageal Reflux
Disease (GORD) in primary care usually receive empiri-
cal treatment based on symptoms, without referral for
endoscopy. Esomeprazole is a new proton pump inhibi-
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tor, which has been shown to be superior to omeprazole
in the healing of reflux oesophagitis. The objective of this
analysis was to compare the cost-effectiveness of acute
treatment for up to eight weeks with esomeprazole, 40
mg, od, or omeprazole, 20 mg, od, in patients with non-
endoscoped GORD. METHODS: Based on results from
clinical studies and from a UK physician survey of patient
management in clinical practice, a simple decision analy-
sis model was designed to compare the cost-effectiveness
of the two treatment strategies. Time with GORD, de-
fined as weeks with endoscopic lesions or weeks with
GORD symptoms, was used as the measure of effective-
ness. UK direct medical costs were used. Results were cal-
culated from a National Health Service perspective. RE-
SULTS: The esomeprazole strategy was dominant over
the omeprazole strategy. Time with GORD was 3.3 weeks
per patient in the esomeprazole strategy and 3.6 weeks in
the omeprazole strategy. The esomeprazole strategy in-
curred lower direct medical costs than the omeprazole
strategy. A sensitivity analysis showed that the results are
sensitive to a change in drug costs for esomeprazole or
omeprazole. However, when costs associated with a
treatment failure after eight weeks are considered, the re-
sults indicate that the esomeprazole strategy is cost-saving
even when drug costs for omeprazole, 20 mg, are reduced
by more than one third. CONCLUSIONS: Esomeprazole
is cost-effective compared with omeprazole for the acute
treatment of patients with non-endoscoped GORD.
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OBJECTIVE: To model the impact of an anti-obesity
treatment in the UK and assess its cost-effectiveness ratio
with the effectiveness measurement defined as QUALYS.
The Scottish Health Survey describes the obese popula-
tion in terms of its risks to develop type 2 diabetes, hy-
perlipidemia and hypertension. The Framingham equa-
tion has then been used to calculate the death rate from
the cardiovascular events. The model splits the obese
population by BMI, age and gender. The diabetes popu-
lation is treated separately and based on published UK-
PDS work. The one-year model calculates the impact of
loosing 10% of weight. A number of life years gained is
identified before adjusting for quality of life. The utility
gain of an obese population going through weight loss is
based on a UK National survey, conducted by the Uni-
versity of York. The sensitivity analysis also includes
other sources of utilities scores. RESULTS: The treat-
ment of obesity over one year results in improvement in
life expectancy as well as quality of life. A clinically sig-
nificant weight loss of 10% appears to be cost-effective,
especially in the type 2 diabetes sub-group. The cost-ef-
fectiveness ratio is below £15,000/QUALYs. 
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OBJECTIVES: Determine age- and gender-specific treat-
ment prevalence rates for overactive bladder (OAB) and
compare resource use and costs among members of a
managed care organization receiving OAB treatment.
METHODS: Administration claims data from 7 United
Health Group affiliated health plans on members diag-
nosed or treated for OAB during 1998 were analyzed.
Resource use and associated costs were assessed over a
four-month follow-up. A total of 22,550 plan members
had either a diagnosis of OAB from March to August
1998 or a pharmacy claim for tolterodine, oxybutynin,
or flavoxate. Of these members, 8,661 met study criteria
and were categorized into four OAB treatment groups. A
multivariate regression analysis was used to determine
the relationship between treatment groups and percent
change in per member per month (PMPM) costs. RE-
SULTS: In 1998, the prevalence of OAB among plan
members was 1.1%. Of the patients with OAB, 71% did
not receive pharmacotherapy. After multivariate analysis,
treatment with tolterodine, oxybutynin, or ‘other’ OAB
treatment did not significantly affect the percent change
in total PMPM costs compared to the no OAB treatment
group. CONCLUSION: While the adjusted percent change
in PMPM pharmacy costs was significantly higher among
subjects in the tolterodine group, medical and total
PMPM costs were not. Clinical studies have shown that
tolterodine is better tolerated than oxybutynin. This in-
formation together with the lack of significantly higher
PMPM costs suggests that tolterodine may be cost-effec-
tive and this may be more conclusively demonstrated in
further studies.
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OBJECTIVE: To adapt a United States-developed Over-
active Bladder (OAB) economic model for use in the
United Kingdom (UK). METHODS: A cost-offset eco-
nomic model was developed in the US to estimate the
cost-effectiveness of tolterodine (Detrusitol) and oxybu-
tynin (ex. Ditropan). The economic model was adapted
for the UK market by changing the medical treatment al-
